Back to Authors

Otzen, Daniel E.

https://orcid.org/0000-0002-2918-8989

Mayo Clinic

Aarhus University

Citations 2

ThT 101: a primer on the use of thioflavin T to investigate amyloid formation
Malmos, Kirsten Gade , Blancas‐Mejía, Luis M. , Weber, Benedikt , Büchner, Johannes , Ramı́rez-Alvarado, Marina , Naiki, Hironobu , Otzen, Daniel E. , Otzen, Daniel , Ramirez-Alvarado, Marina

Amyloid | April 10, 2017 | Volume: 24 | Issue: 1 | Pages: 1-16

10.1080/13506129.2017.1304905 Get It

The neural chaperone proSAAS blocks α-synuclein fibrillation and neurotoxicity
Jarvela, Timothy S. , Lam, Hoa A., Helwig, Michael , Lorenzen, Nikolai, McLean, Pamela J. , Maidment, Nigel T., Otzen, Daniel E. , Lindberg, Iris , McLean, Pamela J

Proceedings of the National Academy of Sciences | July 25, 2016 | Volume: 113 | Issue: 32 | Pages: No page available

10.1073/pnas.1601091113 Get It

Significance Aberrant protein homeostasis (proteostasis) is increasingly recognized as a major causal factor in the development of protein aggregates, including aggregation of α-synuclein in Parkinson’s disease. Cellular proteins known as chaperones control proteostatic processes and are strongly associated with many different neurodegenerative diseases. We show here that an abundant brain- and endocrine-specific secretory chaperone known as proSAAS (named after four residues in the amino terminal region) exhibits potent antiaggregant effects on α-synuclein aggregation, and we identify a region of the protein that is necessary for this antiaggregant effect. We further show that proSAAS expression is able to stop α-synuclein from killing dopaminergic cells in a nigral cell model of Parkinson’s disease. This work demonstrates an important role for the proSAAS protein in blocking aggregation in neurodegeneration.